Final analysis in 514 patients with advanced oesophageal squamous-cell carcinoma: toripalimab plus paclitaxel-cisplatin improved overall survival vs placebo plus chemotherapy (median 17.7 vs 12.9 months; HR 0.72). PD-L1 and TMB did not predict benefit (exploratory).
RCTn = 514
Chen et al. Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase III trial of toripalimab plus chemotherapy in advanced esophageal squamous-cell carcinoma